OTCMKTS:IVBXF Innovent Biologics (IVBXF) Stock Price, News & Analysis $12.14 +0.14 (+1.14%) As of 10/9/2026 02:41 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Innovent Biologics Stock (OTCMKTS:IVBXF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innovent Biologics alerts:Sign Up Key Stats Today's Range$12.14▼$12.1450-Day Range$10.68▼$15.0152-Week Range$9.10▼$15.01Volume3,256 shsAverage Volume3,728 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innovent Biologics, Inc. is a China-based biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines and biosimilars. The company’s research and development activities primarily address oncology, autoimmune diseases, metabolic disorders and other serious medical conditions. Innovent’s portfolio includes therapies such as TYVYT (sintilimab), an immunotherapy used in certain cancer treatments, and olverembatinib, a targeted therapy for specific forms of chronic myeloid leukemia. The company also develops and markets biosimilar products, including treatments based on bevacizumab, adalimumab and rituximab, as well as additional investigational medicines and cell therapies. Founded in 2011 and headquartered in Suzhou, China, Innovent serves the Chinese market and is pursuing international development and commercialization opportunities through research and business partnerships. The company was founded by Dr. Michael Yu, who has served as its chairman and chief executive officer.AI Generated. May Contain Errors. Read More Receive IVBXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovent Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IVBXF Stock News HeadlinesInnovent Biologics (OTCMKTS:IVBXF) Stock Falls 6.2% - Here's What HappenedOctober 1, 2026 | americanbankingnews.comInnovent Biologics, Inc. Announces Updated Phase 1 Clinical Data Of Trispecific Antibody IBI3003 In Patients With Relapsed Or Refractory Multiple MyelomaSeptember 29, 2026 | marketscreener.comMElon just declared war on your phoneSpaceX reportedly agreed to pay 8 billion dollars for a major slice of U.S. wireless spectrum, and shares of AT&T, Verizon, and T-Mobile dropped within hours of the news. Elon Musk called the deal the last critical piece for complete phone coverage in America, fueling speculation about a future device that could challenge the iPhone.October 10 at 1:00 AM | Stansberry Research (Ad)Innovent Biologics, Inc. Announces NMPA Approval of Jaypirca for A New Indication in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Across All Lines of TherapySeptember 28, 2026 | marketscreener.comMInnovent's Jaypirca Gets Expanded NMPA Approval For CLL/SLLSeptember 28, 2026 | rttnews.comAltruist Biologics' Suzhou Facility Clears EMA GMP InspectionSeptember 23, 2026 | rttnews.comHuatai Securities Sticks to Their Buy Rating for Innovent Biologics (IVBXF)September 14, 2026 | theglobeandmail.comInnovent Biologics Details Board and Committee StructureSeptember 1, 2026 | tipranks.comSee More Headlines IVBXF Stock Analysis - Frequently Asked Questions How have IVBXF shares performed this year? Innovent Biologics' stock was trading at $9.75 at the start of the year. Since then, IVBXF shares have increased by 24.5% and is now trading at $12.1373. How do I buy shares of Innovent Biologics? Shares of IVBXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IVBXF CIK1774163 Webwww.innoventbio.com Phone86-512-6956-6088FaxN/AEmployees4,872Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:IVBXF) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersTHE NEXT GREAT FINANCIAL CRISIS (it’s already here)Weiss Ratings was the only independent firm to warn before the 2008 Financial Crisis. Now it is sounding the a...Weiss Ratings | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredInside the Options Play With a High Historical Win RateIan Cooper's newest strategy targets triple-digit returns in just 9 days. It doesn't work every time, but a 73...TradeWins | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTech expert smashes iPhone with golf clubTwenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...Stansberry Research | SponsoredElon’s Hiding a Potential $20 Trillion Monster Inside TeslaElon Musk says there is a product inside Tesla's factories he calls the biggest ever made, ten times bigger th...StocksToTrade | SponsoredOil Surge Predicted…Oil markets are heating up heading into 2026, and Marc Lichtenfeld, Chief Income Strategist at The Oxford Club...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovent Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovent Biologics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
